Physician profile
James M Pearson
NPI 1376548511
$353.39
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $68.41 · 2021: $19.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $143.45 | 2019-2020 | |
| Kaleo, INC. | $37.74 | 2019-2020 | |
| Pfizer INC. | $34.89 | 2019 | |
| Novo Nordisk INC | $32.06 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $31.11 | 2019-2020 | |
| Philips North America LLC | $19.74 | 2019 | |
| Abbvie INC. | $19.64 | 2019 | |
| Tris Pharma INC | $12.78 | 2019 | |
| Shire North American Group INC | $11.13 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.